Ratings by CFRA (Wan Nurhayati)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/22/2026 | Novo Nordisk | NVO | Downgrade | Sell (Hold) |
39.80 (39.43) |
-0.93% | Details | |
| 11/7/2025 | Qiagen NV | QGEN | Maintain | Hold (N/A) |
|
Details | ||
| 10/30/2025 | GlaxoSmithKline | GSK | Upgrade | Buy (Hold) |
45.93 (51.21) |
11.5% | Details | |
| 10/29/2025 | Novartis | NVS | Maintain | Hold (N/A) |
|
Details | ||
| 10/17/2025 | Wipro Ltd. | WIT | Maintain | Hold (N/A) |
|
Details | ||
| 2/5/2025 | GlaxoSmithKline | GSK | Maintain | Hold (N/A) |
|
Details | ||
| 1/21/2025 | Novo Nordisk | NVO | Maintain | Hold (N/A) |
|
Details | ||
| 12/13/2024 | Novo Nordisk | NVO | New Coverage | Hold (N/A) |
108.61 (39.80) |
-63.36% | Details | |
| 12/9/2024 | Roche | RHHBY | New Coverage | Hold (N/A) |
36.51 (59.62) |
63.3% | Details | |
| 4/23/2024 | Novartis | NVS | Maintain | Hold (N/A) |
|
Details |
